Sign in

    Xingjuan (Jane) Chao

    Chief Executive Officer at Ceribell
    Board
    Since October 2015
    Age
    45 years
    Education
    Earned a B.S. in chemistry from Peking University and a Ph.D. in biophysics from Cornell University.
    Tenure
    Joined CBLL in October 2015 as Chief Executive Officer and was promoted to President in July 2016.

    Also at Ceribell

    JSM
    Joseph S. Manni
    Chief Revenue Officer
    RW
    Raymond Woo
    Chief Technology Officer
    SB
    Scott Blumberg
    Chief Financial Officer

    About

    Xingjuan (Jane) Chao, aged 45 as of April 11, 2025 , combines a strong scientific academic background with extensive leadership experience. She earned a B.S. in chemistry from Peking University and a Ph.D. in biophysics from Cornell University, establishing the foundation for a career that spans both research and executive management.

    Before joining CBLL, she garnered significant experience through roles at prominent organizations, including serving as a management consultant at McKinsey & Company (July 2007–January 2013), as Senior Strategy Manager at Novartis AG (January 2013–June 2014), and as Principal Manager of Portfolio Management Strategy at Genentech, Inc. (June 2014–August 2015).

    Since joining CBLL as Chief Executive Officer in October 2015 and later being promoted to President in July 2016, her leadership has been pivotal in steering the company’s strategic direction. Her contributions extend to board memberships and key industry agreements, underscoring a well-rounded professional profile that supports both operational and strategic growth.

    $CBLL Performance Under Xingjuan (Jane) Chao

    Past Roles

    OrganizationRoleDate RangeDetails
    Magnus Medical, Inc. Board of Directors Nov 2021 - Feb 2025 External board position
    CeriBell, Inc. President July 2016 - (pre-CEO transition) Held prior to promotion to CEO
    Genentech, Inc. Principal Manager of Portfolio Management Strategy Jun 2014 - Aug 2015 N/A
    Novartis AG Senior Strategy Manager Jan 2013 - Jun 2014 N/A
    McKinsey & Company Management Consultant Jul 2007 - Jan 2013 N/A

    Fixed Compensation

    Data from  FY 2024
    Component NameAmountPayment ScheduleAdditional Details
    Base Salary$501,000 Annually (effective April 1, 2024) Annual salary for 2024
    Car Travel Reimbursements$32,741 As incurred for travel commute Included under "All Other Compensation"

    Performance Compensation

    Data from  FY 2024

    Annual Cash Bonus

    MetricValueDetails
    Bonus Target$250,500 50% of base salary for 2024
    Actual Bonus$278,055 Paid in early 2025 upon achievement of pre-established company performance objectives
    Performance Weight100% Tied exclusively to corporate performance objectives

    Stock Option Awards

    MetricValueDetails
    Grant DateApril 23, 2024 -
    Shares Awarded166,536 shares Total number of securities underlying the options
    Exercise Price$9.406 per share -
    Vesting ScheduleMonthly over 24 months Beginning May 1, 2024; 1/24th of total shares vest each month, subject to continued service
    Grant-date Fair Value$1,013,233 As disclosed in the Summary Compensation Table
    Performance MetricsN/ANo performance metrics, targets, or thresholds are disclosed for the stock option awards